| 2019 |
Newby DA, Stokes B, Smith AJ, 'A pilot study of a pharmacist-led prescribing program for final-year medical students', BMC MEDICAL EDUCATION, 19 (2019) [C1]
|
|
|
| 2013 |
Halland M, Ansley SJ, Stokes BJ, Fitzgerald MN, Inder KJ, Duggan JM, Duggan A, 'Short- and long-term outcomes for patients with variceal haemorrhage in a tertiary hospital', INTERNAL MEDICINE JOURNAL, 43 234-239 (2013) [C1]
|
|
|
| 2013 |
Garrett T, Stokes B, Brien J-A, 'Perceptions of safety culture in hospital pharmacy: how safe do we think we are?', EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 20 82-87 (2013) [C1]
|
|
|
| 2012 |
Dietz HP, Stokes BJ, 'A plea for professional independence', Medical Journal of Australia, 196 104-105 (2012) [C2]
|
|
|
| 2012 |
Dassanayake WM, Jones AL, Michie PT, Carter GL, McElduff P, Stokes BJ, Whyte IM, 'Risk of road traffic accidents in patients discharged following treatment for psychotropic drug overdose: A self-controlled case series study in Australia', CNS Drugs, 26 269-276 (2012) [C1]
|
|
|
| 2012 |
Stokes BJ, 'mathStatica 2.5 [Review]', Journal of Statistical Software, 47 1-11 (2012) [C2] |
|
|
| 2011 |
Calver L, Stokes BJ, Isbister GK, 'Sedation assessment tool to score acute behavioural disturbance in the emergency department', Emergency Medicine Australasia, 23 732-740 (2011) [C1]
|
|
|
| 2011 |
McGettigan P, Lincz L, Attia JR, McElduff P, Bissett L, Peel R, et al., 'The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene', British Journal of Clinical Pharmacology, 72 707-714 (2011) [C1]
|
|
|
| 2011 |
Henry DA, Carless PA, Moxey AJ, O'Connell DL, Stokes BJ, Fergusson DA, Ker K, 'Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion', Cochrane Database of Systematic Reviews, 2011 1-419 (2011) [C1]
|
|
|
| 2010 |
Isbister GK, Calver L, Page CB, Stokes BJ, Bryant J, Downes MA, 'Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: The DORM Study', Annals of Emergency Medicine, 56 392-401 (2010) [C1]
|
|
|
| 2010 |
Macneill PU, Kerridge IH, Newby DA, Stokes BJ, Doran E, Henry DA, 'Attitudes of physicians and public to pharmaceutical industry 'gifts'', Internal Medicine Journal, 40 335-341 (2010) [C1]
|
|
|
| 2010 |
Macneill PU, Kerridge IH, Newby DA, Stokes BJ, Doran E, Henry DA, 'Questioning the ethics of the ethicists. Reply', Internal Medicine Journal, 40 799-800 (2010) [C3]
|
|
|
| 2010 |
Macneill PU, Kerridge IH, Newby DA, Stokes BJ, Doran E, Henry DA, 'Reply', Internal Medicine Journal, 40 799-800 (2010) [C3]
|
|
|
| 2009 |
Isbister GK, Calver L, Van Gorp F, Stokes BJ, Page CB, 'Inter-rater reliability of manual QT measurement and prediction of abnormal QT,HR pairs', Clinical Toxicology, 47 884-888 (2009) [C1]
|
|
|
| 2009 |
Prajogo J, Neil A, Duke J, Zhang H, Stokes B, Rowlings P, 'MODELING COST-EFFECTIVENESS OF HIGH DOSE CHEMOTHERAPY AS TREATMENT FOR RELAPSED AGGRESSIVE NON-HODGKIN'S LYMPHOMA IN AN AUSTRALIAN SETTING.', Intern Med J, (2009)
|
|
|
| 2009 |
Calver LA, Stokes BJ, Isbister GK, 'The dark side of the moon', Medical Journal of Australia, 191 692-694 (2009) [C1]
|
|
|
| 2009 |
Rashid AH, Brieva JL, Stokes BJ, 'Incidence of contrast-induced nephropathy in intensive care patients undergoing computerised tomography and prevalence of risk factors', Anaesthesia and Intensive Care, 37 968-975 (2009) [C1]
|
|
|
| 2009 |
Prajogo J, Neil A, Duke J, Zhang H, Stokes BJ, Rowlings PA, 'Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting', Internal Medicine Journal, 39 519-526 (2009) [C1]
|
|
|
| 2008 |
Isbister GK, Brown SGA, Miller M, Tankel A, MacDonald E, Stokes BJ, et al., 'A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism: The RAVE study', QJM, 101 557-565 (2008) [C1]
|
|
|
| 2008 |
Isbister GK, Stokes BJ, Buckle NA, Duffull SB, 'Effect of activated charcoal on citalopram-induced QT prolongation - Reply', Annals of Emergency Medicine, 52 87-88 (2008) [C3]
|
|
|
| 2007 |
Henry DA, Carless PA, Moxey AJ, O'Connell DL, Stokes BJ, McClelland B, et al., 'Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion', The Cochrane Database of Systematic Reviews, CD001886 (2007) [C1]
|
|
|
| 2007 |
Collins CE, Warren JM, Neve M, McCoy P, Stokes B, 'Systematic review of interventions in the management of overweight and obese children which include a dietary component.', JBI Libr Syst Rev, 5 1-70 (2007)
|
|
|
| 2007 |
Brown SGA, Isbister GK, Stokes BJ, 'Route of administration of redback spider bite antivenom: Determining clinician beliefs to facilitate Bayesian analysis of a clinical trial', EMA - Emergency Medicine Australasia, 19 458-463 (2007) [C1]
|
|
|
| 2007 |
Collins CE, Warren JM, Hutchesson MJ, McCoy P, Stokes BJ, 'Systematic review of interventions in the management of overweight and obese children which include a dietary component', International Journal of Evidence-Based Healthcare, 5 2-53 (2007) [C1]
|
|
|
| 2007 |
Isbister GK, Friberg LE, Stokes BJ, Buckley NA, Lee C, Gunja N, et al., 'Activated Charcoal Decreases the Risk of QT Prolongation After Citalopram Overdose', Annals of Emergency Medicine, 50 593.e46-600.e46 (2007) [C1]
|
|
|
| 2006 |
Loten C, Stokes BJ, Worsley D, Seymour JE, Jiang S, Isbister GK, 'Randomised controlled trial of hot water (45 degrees C) immersion versus ice packs for pain relief in bluebottle stings', Medical Journal of Australia, 184 329-333 (2006) [C1]
|
|
|
| 2006 |
McNeill PM, Kerridge IH, Henry DA, Stokes BJ, Hill SR, Newby DA, et al., 'Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia', Internal Medicine Journal, 36 571-578 (2006) [C1]
|
|
|
| 2006 |
Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al., 'Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis', Lancet Oncology, 7 741-746 (2006) [C1]
|
|
|
| 2006 |
Collins CE, Warren JM, Hutchesson MJ, McCoy P, Stokes BJ, 'Measuring effectiveness of dietetic interventions in child obesity - A systematic review of randomized trials', Archives of Pediatrics & Adolescent Medicine, 160 906-922 (2006) [C1]
|
|
|
| 2005 |
Zhang H, Stokes BJ, Prajogo J, Rowlings PA, Neil A, Duke JM, 'Modeled cost-effectiveness analysis of autologous haemopoietic stem cell transplantation compared with standard dose chemotherapy for relapsed, aggressive non-Hodgkin's lymphoma', Biology of Blood and Marrow Transplantation, 11 74-75 (2005) [C3] |
|
|
| 2005 |
Buckley NA, Isbister GK, Stokes BJ, Juurlink DN, 'Hyperbaric oxygen for carbon monoxide poisoning: A systematic review and critical analysis of the evidence', Toxicological Reviews, 24 75-92 (2005) [C1]
|
|
|
| 2005 |
Isbister GK, Gray MR, Balit CR, Raven RJ, Stokes BJ, Porges K, et al., 'Funnel-web spider bite: a systematic review of recorded clinical cases', Medical Journal of Australia, 182 407-411 (2005) [C1]
|
|
|
| 2005 |
Henry DA, Kerridge IH, Hill SR, McNeill PM, Doran E, Newby DA, et al., 'Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience', Medical Journal of Australia, 182 557-560 (2005) [C1]
|
|
|
| 2005 |
Kerridge I, Maguire JM, Newby DA, McNeill PM, Henry DA, Hill SR, et al., 'Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations', Internal Medicine Journal, 35 206-210 (2005) [C1]
|
|
|
| 2005 |
Carless PA, Moxey AJ, Stokes BJ, Henry DA, 'Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials', BMC Cardiovascular Disorders, 5 (2005) [C1]
|
|
|
| 2004 |
Carless PA, Stokes BJ, Moxey AJ, Henry DA, 'Desmopressin for minimising perioperative allogenic blood transfusion', Cochrane Database of Systematic Reviews, - CD001884 (2004) [C1]
|
|
|
| 2001 |
Henry DA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, et al., 'Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.', Cochrane database of systematic reviews (Online), (2001)
BACKGROUND: Concerns regarding the safety of transfused blood have prompted re-consideration of the use of allogeneic (blood from an unrelated donor) blood transfusion. OBJECTIVES... [more] BACKGROUND: Concerns regarding the safety of transfused blood have prompted re-consideration of the use of allogeneic (blood from an unrelated donor) blood transfusion. OBJECTIVES: To assess the effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid, and epsilon aminocaproic acid, on peri-operative red blood cell (RBC) transfusion. SEARCH STRATEGY: We searched MEDLINE (to May 1998), EMBASE (to December 1997), web sites of international health technology assessment agencies (to May 1998). References in identified trials and review articles were checked and authors contacted to identify any additional studies. SELECTION CRITERIA: Randomised controlled trials of anti-fibrinolytic drugs in adults scheduled for non-urgent surgery. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. MAIN RESULTS: We found 61 trials of aprotinin (7027 participants). Aprotinin reduced the rate of RBC transfusion by a relative 30% (RR=0.70: 95%CI: 0.64 to 0.76). The average absolute risk reduction (ARR) was 20.4% (95%CI: 15.6% to 25.3%). On average, aprotinin use saved 1.1 units of RBC (95%CI: 0.69 to 1.47) in those requiring transfusion. Aprotinin also significantly reduced the need for re-operation due to bleeding (RR=0.40: 95%CI: 0.25 to 0.66). We found 18 trials of tranexamic acid (TXA) (1,342 participants). TXA reduced the rate of RBC transfusion by a relative 34% (RR=0.66: 95%CI: 0.54 to 0.81). This represented an ARR of 17.2% (95%CI: 8.7% to 25.7%). TXA use resulted in a saving of 1.03 units of RBC (95%CI: 0.67 to 1.39) in those requiring transfusion. We found four trials of epsilon aminocaproic acid (EACA) (208 participants). EACA use resulted in a statistically non-significant reduction in RBC transfusion (RR=0.48: 95%CI: 0.19 to 1.19). Comparisons between agents Eight trials made 'head-to-head' comparisons between TXA and aprotinin. There was no significant difference between the two drugs in the rate of RBC transfusion: RR=1.21 (95%CI: 0.83 to 1.76) for TXA compared to aprotinin. Adverse Effects Aprotinin did not seem to be associated with an excess risk of adverse effects, including thrombo-embolic events (thrombosis RR=0.64: 95%CI: 0.31 to 1.31) and renal failure (RR=1.19: 95%CI: 0.79 to 1.79). Fewer data were available for TXA and EACA. REVIEWER'S CONCLUSIONS: From this review it appears that aprotinin reduces the need for red cell transfusion, and the need for re-operation due to bleeding, without serious adverse effects. However, there was significant heterogeneity in trial outcomes, and some evidence of publication bias. Similar trends were seen with TXA and EACA, although the data were rather sparse. The poor evaluation of these latter drugs is unfortunate as results suggest they may be equally as effective as aprotinin, but are significantly cheaper. The evidence reviewed here supports the use of aprotinin in cardiac surgery. Further small trials of this drug are not warranted. Future trials should be large enough to compare the efficacy and cost-effectiveness of aprotinin with that of TXA and EACA.
|
|
|
